Hepatitis B Treatment Market

Global Hepatitis B Treatment Market by Types (Chronic and Acute), Treatments (Antiviral Drugs [Entecavir, Lamivudine, Telbivudine, Tenofovir Disoproxil, and Others], Immune Modulator Drugs [Interferon Alpha and Pegylated Interferon], Surgery, and Vaccine), Distribution Channels (Online Pharmacies and Hospital & Retail Pharmacies), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) Forecasts, 2021-2028

  • Report ID: HC-4120
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 176
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global hepatitis B treatment market is anticipated to expand at a robust CAGR during the forecast period, between 2021 and 2028. Hepatitis is mainly caused by liver infection, which can be caused by excessive consumption of alcohol and drugs, or due to certain medical problems. The disease is contagious and some of the common sources for transmission of the disease are due to coming into contact with consuming contaminated water, infected blood, and using infected syringes or needles. Sexual transmission of Hepatitis B can be happened due to frequent intercourse with sex workers, unprotected sex practices, and sex with several partners. Hepatitis B patients are likely to experience a variety of symptoms including weakness, loss of appetite, dark-colored urine, jaundice, swelling in the legs, itching on the skin, drowsiness, weight loss, and others.


Hepatitis B Treatment Market key takeaways

Market Trends, Drivers, Restraints, and Opportunities:

  • Favorable government support for raising hepatitis awareness as well as the growing availability of technologically improved for therapy medicines are projected to propel market expansion during the forecast period.
  • Rising global prevalence of Hepatitis B, increasing number of the elderly population, and rising incidence of viral infection are key factors driving market growth.
  • Increasing prevalence of sexually transmitted illnesses and rising healthcare spending are expected to boost the market expansion in the coming years.
  • Negative effects from treatment and drugs applications are major challenges that can hinder the market growth.
  • The COVID-19 pandemic and high medicine prices are acting as key restraining factors hampering the overall market revenue.
  • Introduction of new treatment devices and massive R&D programs for the development of innovative treatment methods are projected to provide significant growth opportunities for the market.

Scope of the report:

The report on the global hepatitis B treatment market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Attributes

Details

Report Title

Hepatitis B Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018 & 2019

Forecast Period

2021–2028

Segmentation

Types (Chronic and Acute), Treatments (Antiviral Drugs [Entecavir, Lamivudine, Telbivudine, Tenofovir Disoproxil, and Others], Immune Modulator Drugs [Interferon Alpha and Pegylated Interferon], Surgery, and Vaccine), Distribution Channels (Online Pharmacies and Hospital & Retail Pharmacies)

Regional Scope

Asia Pacific, North America, Europe, Latin America, and Middle East & Africa

Report Coverage

Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast

Key Players Covered

Arbutus Biopharma; Dynavax Technologies; Gilead Sciences, Inc.; AbbVie Inc.; Janssen Global Services, LLC; Bristol-Myers Squibb Company; and KM Biologics

 

Hepatitis B Treatment Market Segment Insights:

Chronic segment is projected to hold significant market share

Based on types, the hepatitis B treatment market is bifurcated into chronic and acute. The chronic segment is projected to hold significant market share due to wide prevalence of acute illness of the disease. The treatment for hepatitis B involves a rigid process of diagnosis evaluating medical history and physical examination of patients. Moreover, the treatment of chronic illness includes blood tests, liver function testing, and ultrasound to prevent from severe consequences such as chronic liver disease, liver cancer, and cirrhosis.


Hepatitis B Treatment Market by types

Vaccine segment is anticipated to account for substantial share

On the basis of treatments, the market is segmented into antiviral drugs, immune modulator drugs, surgery, and vaccine. The antiviral drugs segment is further divided into entecavir, lamivudine, telbivudine, tenofovir disoproxil, and others. Furthermore, the immune modulator drugs segment is sub-categorized as interferon alpha and pegylated interferon. The vaccine segment is anticipated to account for a substantial share. The hepatitis B vaccination is made up of viral envelope proteins as well as hepatitis B surface antigens. Yeast cells are used to make the vaccine that can protect against infection as well as halt the progression of liver cancer and chronic disease caused by the illness. Growing awareness regarding the need for better healthcare services presents another key factor driving the segment growth.

Hospital & retail pharmacies segment to register a healthy growth rate

In terms of distribution channels, the hepatitis B treatment market is bifurcated into online pharmacies and hospital & retail pharmacies. The hospital & retail pharmacies segment is expected to register a healthy growth rate during the forecast period owing to the wide availability of treatment drugs and devices in hospitals and retail pharmacies. Moreover, the presence of qualified healthcare experts and reliability of prescribed medications are key factors driving the segment expansion. Furthermore, patients’ preference for hospitals visit for diagnosis due to availability of advanced facilities and specialized medical teams present another major aspects for the segment growth.

North America is expected to dominate the market

In terms of regions, the market is classified as Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to dominate the market due to the rising rate of bacterial illness, advancements in clinical techniques, and the accessibility and availability of the finest therapies for viral infection in this region. Furthermore, high healthcare expenditure and increasing number of hepatitis incidence, and mortality from hepatitis are major drivers of the regional market. Furthermore, high rates of adoption of sophisticated therapies, advantageous reimbursement policies, and the presence of well-established healthcare infrastructure are all contributing to the overall regional growth. Additionally, the presence of leading market players coupled with expanding awareness initiatives and new product launches are factors boosting the overall market expansion in the region.


Hepatitis B Treatment Market by regions

Segments

Segments Covered in the Report:

By Types

  • Chronic
  • Acute
By Treatments
  • Antiviral Drugs
    • Entecavir
    • Lamivudine
    • Telbivudine
    • Tenofovir Disoproxil
    • Others
  • Immune Modulator Drugs
    • Interferon Alpha
    • Pegylated Interferon
  • Surgery
  • Vaccine
By Distribution Channels
  • Online Pharmacies
  • Hospital & Retail Pharmacies
By Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
By Key Players
  • Arbutus Biopharma
  • Dynavax Technologies
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Janssen Global Services, LLC
  • Bristol-Myers Squibb Company
  • KM Biologics

Competitive Landscape

Key players in the global hepatitis B treatment market are Arbutus Biopharma; Dynavax Technologies; Gilead Sciences, Inc.; AbbVie Inc.; Janssen Global Services, LLC; Bristol-Myers Squibb Company; and KM Biologics. These players have adopted several market development activities including collaborations, agreements, mergers & acquisitions, production capacity expansion, new product launches, and partnerships to increase their market share.

Hepatitis B Treatment Market by key players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hepatitis B Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Hepatitis B Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Hepatitis B Treatment Market - Supply Chain
  4.5. Global Hepatitis B Treatment Market Forecast
     4.5.1. Hepatitis B Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Hepatitis B Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Hepatitis B Treatment Market Absolute $ Opportunity
5. Global Hepatitis B Treatment Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Hepatitis B Treatment Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Hepatitis B Treatment Demand Share Forecast, 2019-2026
6. North America Hepatitis B Treatment Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Hepatitis B Treatment Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Hepatitis B Treatment Demand Share Forecast, 2019-2026
7. Latin America Hepatitis B Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Hepatitis B Treatment Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Hepatitis B Treatment Demand Share Forecast, 2019-2026
8. Europe Hepatitis B Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Hepatitis B Treatment Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Hepatitis B Treatment Demand Share Forecast, 2019-2026
9. Asia Pacific Hepatitis B Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Hepatitis B Treatment Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Hepatitis B Treatment Demand Share Forecast, 2019-2026
10. Middle East & Africa Hepatitis B Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Hepatitis B Treatment Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Hepatitis B Treatment Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Hepatitis B Treatment Market: Market Share Analysis
  11.2. Hepatitis B Treatment Distributors and Customers
  11.3. Hepatitis B Treatment Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Arbutus Biopharma
     11.4.2. Dynavax Technologies
     11.4.3. Gilead Sciences, Inc.
     11.4.4. AbbVie Inc.
     11.4.5. Janssen Global Services, LLC
     11.4.6. Bristol-Myers Squibb Company
     11.4.7. KM Biologics

Segments Covered in the Report:

By Types

  • Chronic
  • Acute
By Treatments
  • Antiviral Drugs
    • Entecavir
    • Lamivudine
    • Telbivudine
    • Tenofovir Disoproxil
    • Others
  • Immune Modulator Drugs
    • Interferon Alpha
    • Pegylated Interferon
  • Surgery
  • Vaccine
By Distribution Channels
  • Online Pharmacies
  • Hospital & Retail Pharmacies
By Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
By Key Players
  • Arbutus Biopharma
  • Dynavax Technologies
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Janssen Global Services, LLC
  • Bristol-Myers Squibb Company
  • KM Biologics

Key players in the global hepatitis B treatment market are Arbutus Biopharma; Dynavax Technologies; Gilead Sciences, Inc.; AbbVie Inc.; Janssen Global Services, LLC; Bristol-Myers Squibb Company; and KM Biologics. These players have adopted several market development activities including collaborations, agreements, mergers & acquisitions, production capacity expansion, new product launches, and partnerships to increase their market share.

Hepatitis B Treatment Market by key players

Buy Report